Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
58.15 HKD | +0.61% |
|
-3.41% | +2.83% |
Jun. 28 | Angelalign Technology Inc. Approves the Special Dividend for the Year Ended December 31, 2023 | CI |
May. 01 | Angel Aligner Accelerates Expansion with Enhanced Features and a Canadian Launch | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 123.41 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.08 times its current sales, is high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.83% | 1.25B | D- | ||
-13.02% | 20.9B | B | ||
-0.44% | 18.08B | A | ||
+1.76% | 9.39B | B- | ||
+8.20% | 1.84B | B+ | ||
-30.74% | 1.73B | - | ||
-5.81% | 491M | - | ||
0.00% | 347M | - | - | |
+96.15% | 227M | - | ||
+23.55% | 105M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 6699 Stock
- Ratings Angelalign Technology Inc.